OPTHEA LIMITED (OPT)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

OPT

OPT - OPTHEA LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -1.03
Index: ASX300 | ALL-ORDS

Opthea is an Australian healthcare company specialising in the development and commercialisation of therapies to combat eye diseases. Founded in 1984, the company listed on the ASX in 1991.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.60

02 Apr
2025

0.000

OPEN

$0.60

0.000

HIGH

$0.60

0

LOW

$0.60

TARGET
$0.05 -91.7% downside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
OPT: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx - 52.7 - 26.6 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-52.7
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.2 M
Book Value Per Share xxxxxxxxxxxxxxx-10.4
Net Operating Cash Flow xxxxxxxxxxxxxxx-245.7 M
Net Profit Margin xxxxxxxxxxxxxxx-176,665.73 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-
Return on Invested Capital xxxxxxxxxxxxxxx-377.45 %
Return on Assets xxxxxxxxxxxxxxx-156.01 %
Return on Equity xxxxxxxxxxxxxxx-
Return on Total Capital xxxxxxxxxxxxxxx-328.49 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-245.8 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx300 M
Total Debt xxxxxxxxxxxxxxx300 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx258 M
Price To Book Value xxxxxxxxxxxxxxx-

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx0.1 M
Capex % of Sales xxxxxxxxxxxxxxx26.86 %
Cost of Goods Sold xxxxxxxxxxxxxxx0 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx293 M
Research & Development xxxxxxxxxxxxxxx269 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

-1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

02/04/2025

5

Downgrade to Sell from Buy

$0.05

-91.67%

Bell Potter notes the failure of Opthea's two global phase 3 trials is the "absolute worst-case" outcome, forcing the company to discontinue further development of sozinibercept.

While this does not automatically terminate the company's DFA agreement, the broker notes bankruptcy could provide such grounds.

The broker highlights the company had US$100m cash at the end of March, which wouldn't be sufficient to repay DFA investors once vendor contracts are paid out.

Target dropped to $0.05 from $1.30. Rating downgraded to Sell from Speculative Buy.

FORECAST
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -26.60 cents.
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -0.40 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

xx/xx/xxxx

1

xxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Wilsons

27/03/2025

3

Market Weight

$1.00

66.67%

Wilsons notes Opthea's COAST phase III trial for the sozinibercept drug failed, which could adversely impact the biotech's solvency.

The broker's Market Weight rating and $1.00 target price are under review.

The broker's $1.00 share price had assumed a positive outcome on the trial.

FORECAST
Wilsons forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -11.00 cents.
Wilsons forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -4.50 cents.
Access Extra Coverage Research History >

OPT STOCK CHART

FNArena News on OPT

1
March In Review: Gold Shines As Tech Suffers

1:08 PM - Australia
2
Australian Broker Call *Extra* Edition – Apr 01, 2025

Apr 01 2025 - Daily Market Reports
3
Rudi’s View: Coal, Copper, Car Group & More

Mar 27 2025 - Rudi's View
4
Australian Broker Call *Extra* Edition – Mar 27, 2025

Mar 27 2025 - Daily Market Reports
5
In Brief: Top Picks In Financials, Retail & Healthcare

Mar 07 2025 - Weekly Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Behring Margin Outlook Still Main Game For CSL

Feb 13 2025 - Australia
2
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
3
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
4
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
5
CSL Shares Breaking Free

Jul 23 2024 - Technicals
6
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
7
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
8
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
9
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps
10
Dr Boreham’s Crucible: Island Therapeutics

Jun 17 2024 - Small Caps